KIT and neoplasm: Anlotinib targets vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), platelet‐derived growth factor receptors (PDGFRs), and stem cell factor receptors (c‐kit),14 thereby exerting inhibitory effects on tumor growth and angiogenesis.15, 16